Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
7 s0 `; _: b* M
$ e: `! I8 Q: y0 \1 e b' y3 y) D% y. a) C" X6 b3 |! f
Sub-category:
& m! X; C: W& l& PMolecular Targets
( B. L3 _# S9 ?) }/ @) s' a( |; `2 V# y' \& N
6 n9 k- N" C8 A. t) }/ D
Category:- b- c) o1 e) U. e. l3 L9 K
Tumor Biology ' o7 t& _: m+ A9 W" U. J
) `$ O! `& p. U, w, C5 b, e
; \5 I0 _0 u: w5 r; h
Meeting:! W" {/ o1 x k4 g6 i/ j) r* f
2011 ASCO Annual Meeting
7 c4 O9 O% C+ W; x6 P& x
( s1 Z& ^5 l9 `2 B/ R$ @6 J- @6 Y+ b I: y* [
Session Type and Session Title:& s' i- T+ {# D) E" K
Poster Discussion Session, Tumor Biology 5 f3 t# b1 ?7 _. M
- M, |7 Q5 {# `) E. f+ l- S3 u* t; c
+ l9 @! U5 {9 R3 dAbstract No:
2 B+ g3 X' X. `. c3 J( ]3 t& @' u10517 ' H% |$ n8 X# Z( ~
+ M- L. d8 D6 c/ r3 `# D$ g S7 h- F# e
Citation:& v) v: K. I) g: n
J Clin Oncol 29: 2011 (suppl; abstr 10517) + _/ j) H5 t4 a
( l4 t( T& n* |! x- r# [2 \: S' m) l9 p& y O( C( X' S* }% O# y
Author(s): L6 ^8 A1 {% |8 g ^2 T4 O
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
V% [* e- X. M6 l1 A! j; d0 o: p7 d0 d8 q/ l* O
9 R" B/ A' S- I: C; l+ L5 v0 W9 m( M$ L) n. E1 N
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
+ A+ q1 i8 m8 s6 u, t. _
; ^# L) h# r: @0 ^! }. B+ TAbstract Disclosures
: H$ L4 t6 ^1 Y' @8 \& b: L1 i9 D* l" r- o+ A. i3 U3 d6 J
Abstract:1 t0 s3 q# G$ r- x: t3 }# [8 g+ s
- U3 s. }1 e9 C; r
3 V7 M, i5 M, I! [& xBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.1 m' S9 ~/ D, y6 V3 W m+ d
; e$ l; x% f7 k& _ K
1 t' y5 U& Z6 m& ~" N |
) J) Y! H! h: a7 f& t
显身卡
